Considering the expression of CD1d in CLL, MM, and AML, and the favorable tolerability profile of the surrogate engager in NHPs, the CD1d-Vδ2 hu-bsTCE was termed LAVA-051 and selected for evaluation in a first-in-human clinical phase 1/2a study in patients with CLL, MM, or AML that are refractory to prior therapy (ClinicalTrials.gov identifier: NCT04887259). Here, CD1D is linked to acute myeloid leukemia.